NCT06699914View on ClinicalTrials.gov

A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)

CompletedOBSERVATIONAL
Enrollment

438

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Neovascular Age-Related Macular Degeneration
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY